These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

565 related items for PubMed ID: 8290968

  • 21. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
    Oriol A, Ribera JM, Esteve J, Guàrdia R, Brunet S, Bueno J, Pedro C, Llorente A, Tormo M, Besalduch J, Sánchez JM, Batlle M, Vivancos P, Carreras E, Vilà JM, Julià A, Sierra J, Montserrat E, Feliu E, CETLAM AML-99.
    Haematologica; 2004 Jul; 89(7):791-800. PubMed ID: 15257930
    [Abstract] [Full Text] [Related]

  • 22. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [Abstract] [Full Text] [Related]

  • 23. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia.
    Archimbaud E, Fenaux P, Reiffers J, Cordonnier C, Leblond V, Travade P, Troussard X, Tilly H, Auzanneau G, Marie JP.
    Leukemia; 1993 Mar; 7(3):372-7. PubMed ID: 8445942
    [Abstract] [Full Text] [Related]

  • 24. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
    Clavio M, Gatto S, Beltrami G, Quintino S, Canepa L, Pierri I, Galbusera V, Carrara P, Miglino M, Varaldo R, Ballerini F, Venturino C, Cerri R, Risso M, Balleari E, Carella AM, Sessarego M, Ghio R, Bacigalupo A, Gobbi M.
    J Exp Clin Cancer Res; 2002 Dec; 21(4):481-7. PubMed ID: 12636093
    [Abstract] [Full Text] [Related]

  • 25. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
    Farag SS, Ruppert AS, Mrózek K, Mayer RJ, Stone RM, Carroll AJ, Powell BL, Moore JO, Pettenati MJ, Koduru PR, Stamberg J, Baer MR, Block AW, Vardiman JW, Kolitz JE, Schiffer CA, Larson RA, Bloomfield CD.
    J Clin Oncol; 2005 Jan 20; 23(3):482-93. PubMed ID: 15534356
    [Abstract] [Full Text] [Related]

  • 26. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
    Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, Reiter A, Ritter J, Dworzak M, Stary J, Reinhardt D.
    J Clin Oncol; 2006 Sep 20; 24(27):4499-506. PubMed ID: 16983120
    [Abstract] [Full Text] [Related]

  • 27. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
    Wrzesień-Kuś A, Robak T, Wierzbowska A, Lech-Marańda E, Pluta A, Wawrzyniak E, Krawczyńska A, Kuliczkowski K, Mazur G, Kiebiński M, Dmoszyńska A, Wach M, Hellmann A, Baran W, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Polish Adult Leukemia Group.
    Ann Hematol; 2005 Sep 20; 84(9):557-64. PubMed ID: 15856358
    [Abstract] [Full Text] [Related]

  • 28. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
    Bow EJ, Gallant G, Williams GJ, Woloschuk D, Shore TB, Rubinger M, Schacter BA.
    Cancer; 1998 Oct 01; 83(7):1344-54. PubMed ID: 9762935
    [Abstract] [Full Text] [Related]

  • 29. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
    Park HS, Kim DW, Kim CC, Kim HK, Kim JS, Hwang TJ, Kim HJ, Kim HS, Song HS, Park JW, Ahn HS, Chung TJ, Cho KS, Lee KS, Choi YM.
    Semin Hematol; 1996 Oct 01; 33(4 Suppl 3):24-9. PubMed ID: 8916313
    [Abstract] [Full Text] [Related]

  • 30. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia.
    Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, Gatti AM, Cerri R, Celesti L, Vallebella E, Sessarego M, Patrone F, Ghio R, Damasio E, Gobbi M.
    Haematologica; 1996 Oct 01; 81(6):513-20. PubMed ID: 9009438
    [Abstract] [Full Text] [Related]

  • 31. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
    Archimbaud E, Jehn U, Thomas X, De Cataldo F, Fillet G, Belhabri A, Peaud PY, Martin C, Amadori S, Willemze R.
    Leukemia; 1999 Jun 01; 13(6):843-9. PubMed ID: 10360370
    [Abstract] [Full Text] [Related]

  • 32. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
    Alymara V, Tzouvara E, Vartholomatos G, Chaidos A, Tsiara S, Bourantas KL.
    J Exp Clin Cancer Res; 2004 Sep 01; 23(3):447-54. PubMed ID: 15595635
    [Abstract] [Full Text] [Related]

  • 33. [Improved treatment results in children with AML: Results of study AML-BFM 93].
    Creutzig U, Berthold F, Boos J, Fleischhack G, Gadner H, Gnekow A, Graubner U, Henze G, Hermann J, Imbach P, Jürgens H, Kabisch H, Körholz D, Niemeyer CM, Reinhardt D, Reiter A, Ritter J, Spaar HJ, Zimmermann M, AML-BFM-Studien-Gruppe.
    Klin Padiatr; 2001 Sep 01; 213(4):175-85. PubMed ID: 11528551
    [Abstract] [Full Text] [Related]

  • 34. Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia.
    Mehta J, Powles R, Singhal S, Horton C, Hamblin M, Zomas A, Saso R, Prendiville J, Glynne P, Allford S, Mackay H, Treleaven J.
    Semin Hematol; 1996 Oct 01; 33(4 Suppl 3):18-23. PubMed ID: 8916312
    [Abstract] [Full Text] [Related]

  • 35. Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.
    Thomas X, Elhamri M, Chelghoum Y, Reman O, Arnaud P, Raffoux E, Le QH, Tavernier E, Dombret H, Michallet M.
    Ann Hematol; 2005 Jun 01; 84(6):376-82. PubMed ID: 15782343
    [Abstract] [Full Text] [Related]

  • 36. A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.
    Koc Y, Oyan B, Kars A, Tekuzman G, Canpinar H, Kansu E.
    Hematol Oncol; 2004 Jun 01; 22(2):43-53. PubMed ID: 15386563
    [Abstract] [Full Text] [Related]

  • 37. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N, Thomas V, Abrahams L, du Toit C, McDonald A.
    Am J Hematol; 2004 Aug 01; 76(4):319-29. PubMed ID: 15282663
    [Abstract] [Full Text] [Related]

  • 38. [High-dose chemoradiotherapy combined with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) followed by autologous peripheral blood stem cell transplantation (PBSCT) in a case of refractory acute myelogenous leukemia (AML)].
    Tanosaki R, Okamoto S, Takahashi S, Inoue T, Kikuno K, Aoki Y, Takada M, Irie S, Shimane M, Tojo A.
    Rinsho Ketsueki; 1993 Aug 01; 34(8):946-51. PubMed ID: 8105115
    [Abstract] [Full Text] [Related]

  • 39. Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
    Visani G, Lemoli RM, Isidori A, Piccaluga PP, Martinelli G, Malagola M, Gugliotta L, Bonini A, Bonifazi F, Motta MR, Rizzi S, Castellani S, Tura S.
    Bone Marrow Transplant; 2001 Apr 01; 27(8):829-35. PubMed ID: 11477440
    [Abstract] [Full Text] [Related]

  • 40. Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia.
    Bassan R, Lerede T, Borleri G, Chiodini B, Rossi A, Buelli M, Rambaldi A, Viero P, Barbui T.
    Haematologica; 2002 Mar 01; 87(3):257-63. PubMed ID: 11869937
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.